Axel Hinke

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

Helmut Oettle, P. Neuhaus, Andreas Hochhaus et al. · JAMA · 2013 · 1.8K citations

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Lymphoid Neoplasia, Rituximab Versus Chop, Oncology +10

Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

Thomas Wiegel, Dirk Bottke, Ursula Steiner et al. · Journal of Clinical Oncology · 2009 · 815 citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann, D. Quietzsch, Frank Gieseler et al. · Journal of Clinical Oncology · 2006 · 682 citations

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience, Albrecht Kretzschmar, Dmitry Bichev et al. · European Journal of Cancer · 2011 · 608 citations

Oncology, Gastrointestinal Oncology, Cancer Management +8